BeiGene Medical Europe
 acceso
 
  • Congreso virtual
  • Contacto
  • memoinOncology
  • beigenemedical.info

Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors

 Volver  Ver
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
 POSTER   09/2020
 Download  Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Rating

Rate this publication

Publicaciones relacionadas

Tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC
Tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)
Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)
 Volver

Esta función sólo está disponible para usuarios registrados.

BeiGene Medical EU
Bienvenido al sitio web de información médica de BeiGene EU
EuropeWorldItalySpain
No soy un profesional de la salud
Ahora está saliendo del sitio web de BeiGene EU.
You are now leaving the italian website of BeiGene EU.
BeiGene Medical EU
Please check your webbrowser
BeiGene Medical Europe
beigenemedical.eu
  • Congreso virtual
Este sitio web contiene información sobre productos de investigación que aún no han sido aprobados por la Agencia Europea del Medicamento para el tratamiento de ninguna enfermedad. Para más información, contacte con medicalinformationEU@beigene.com.
© 2022 BeiGene. All Rights Reserved.
Política de privacidad | Condiciones | Publicado por |